Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

Axion BioSystems Adds Affordable Maestro Volttm to its Industry-Leading MEA System Lineup


Axion BioSystems today announced the launch of the new Maestro Volttm, an affordable benchtop microelectrode array (MEA) system designed to meet the demands of academic labs with lower throughput needs and limited budgets. Featuring the same ease of use, high-quality controls, and intuitive software synonymous with the Maestro name, the 6-well Maestro Volt is available for both neurological and cardiovascular research applications. The new device expands Axion's flagship Maestro product line and promises to drive scientific discovery by making MEA technology more broadly available.

"Since its founding in 2008, Axion's goal has been to make MEA tools more accessible to scientists studying electrically active cells like neurons and cardiomyocytes. It is gratifying to see how Maestro MEA is increasingly being used in groundbreaking disease research and therapeutic development for Alzheimer's disease, Parkinson's disease, epilepsy, glioblastoma, and others?but budget limitations have put the technology out of reach for some," said Julien Bradley, Chief Executive Officer at Axion BioSystems. "With the addition of the affordable Maestro Volt to our industry-leading product suite, we hope to put the power of Maestro MEA in every lab."

Accurately evaluating electrically active cells in vitro over time is essential in neurological and cardiovascular research. Axion BioSystems' next-generation Maestro MEA platform, which also includes the high-throughput Maestro Protm and the versatile Maestro Edgetm, makes it easy for any scientist to noninvasively measure dynamic electrical activity in 2D and 3D cell models over days, weeks, or months with no labels, dyes, or complicated steps. Using MEA technology, researchers can reveal new insights into the pathogenesis and progression of disease, identify novel druggable targets, explore precision medicine solutions, accelerate regenerative medicine research, and investigate the impact of toxic substances on brain and heart health.

About Axion BioSystems

Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices worldwide. www.axionbiosystems.com


These press releases may also interest you

at 02:21
Elbit Systems Ltd.  ("Elbit Systems" or the "Company") announced today, further to the report in its Annual Report on Form 20-F for the year ended December 31, 2023, filed on March 28, 2024, that it was awarded a group of contracts in an aggregate...

at 02:05
OneStock SAS, a leading provider of Order Management Systems (OMS), today announced a $72 million investment from global growth equity investor Summit Partners. OneStock was founded in 2015 by CEO, Romulus Grigoras, and CTO, Benoit Baccot, to help...

at 02:05
Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and...

at 02:00
ASOTO OÜ and CATALSYS Limited are thrilled to announce a strategic joint venture aimed at transforming the European data-center industry through innovative green-energy solutions. This partnership combines ASOTO's expertise in off-grid power...

at 02:00
Vantage Foundation proudly announces its partnership with Teach For Malaysia (TFM) to empower indigenous Orang Asli communities in Malaysia through education. This collaboration underscores Vantage Foundation's mission to shine the spotlight on the...

at 02:00
 Novo Holdings and A.P. Moller Holding have enabled a ?150 million fundraise for CIRCTEC by leading with a ?75 million equity investment. Financing includes ?22.5 million of grants awarded by the Government of the Netherlands.The funding...



News published on and distributed by: